Efficacy evaluation of polysaccharide nucleic acid-fraction of BCG on vasomotor rhinitis.
- Author:
Jianjun CHEN
1
;
Weijia KONG
;
Yue ZHOU
;
Jisheng XIANG
;
Hong SHU
;
Qiumei SHI
;
Huifang TAN
Author Information
1. Department of Otorhinolaryngology, Union Hospital, Huazhong University of Science and Technology, Wuhan, 430022, China. jj-c@tom.com
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
BCG Vaccine;
adverse effects;
therapeutic use;
Female;
Humans;
Male;
Middle Aged;
Rhinitis, Vasomotor;
drug therapy;
Single-Blind Method;
Young Adult
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2008;22(5):201-203
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the efficacy and safety of polysaccharide nucleic acid-fraction (BCG-PSN) in the treatment of vasomotor rhinitis.
METHOD:Sixty patients were randomly divided into BCG-PSN group (n = 30) and control group (n = 30). The patients in BCG-PSN group were administered with BCG-PSN 1.0 mg twice a week for two months, and intranasal azelastine was used if needed. The patients in control group were administered with intranasal azelastine solely twice a day, which could be decreased with the symptom relief. Follow-up was 6 months. Symptom and medication scores were recorded. Side effects were registered.
RESULT:The symptom and medication scores of BCG-PSN group were significantly lower than that of control group (P < 0.01) after BCG-PSN treatment. There was no significant difference in symptom score between the two groups at 6 months after BCG-PSN treatment (P > 0.05), while the medication score of BCG-PSN group was still much lower than that of control group (P < 0.01). No serious adverse events were reported in BCG-PSN group except for local pain on the injection place in one patient.
CONCLUSION:BCG-PSN is effective and safe in the treatment of vasomotor rhinitis.
